A recent study reported that the expression levels of IL6 and IL8 in triple-negative breast cancer (TNBC) were associated with cell survival, and that the inhibition of IL6/IL8 signaling was a therapeutic strategy for improving the prognosis of patients with TNBC (45). This evidence concerns the gene IL6 and triple-negative breast carcinoma.